SCHEMBL5957735

SCHEMBL5957735

O=c1[nH]c2ccccc2nc1-c1cc2cc(O)ccc2[nH]1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.52
NPC1 O15118 5/20 0.52
KDM4E B2RXH2 5/20 0.52
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
MAPT P10636 2/20 0.48
HTT P42858 1/20 0.48
PLAUR Q03405 1/20 0.48
AURKA O14965 3/20 0.47
ADORA3 P0DMS8 1/20 0.47
ADORA1 P30542 1/20 0.47
GAA P10253 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
CASP1 P29466 2/20 0.47
CASP7 P55210 2/20 0.47
HSD17B10 Q99714 2/20 0.47
LMNA P02545 1/20 0.47
GLA P06280 1/20 0.47
PDGFRB P09619 2/20 0.46
PDGFRA P16234 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5957715 0.86 RAB9A (0.61) RAB9ANPC1KDM4EMEN1KMT2A
SCHEMBL5957992 0.83 RAB9A (0.52) RAB9ANPC1KDM4EMEN1KMT2A
SCHEMBL27488931 0.76 KDR (0.77) AURKAPDGFRBPDGFRAFLT3KDR
SCHEMBL5957575 0.75 RAB9A (0.43) RAB9ANPC1KDM4EMEN1KMT2A
SCHEMBL5957684 0.74 RAB9A (0.44) RAB9ANPC1KDM4EMEN1KMT2A
SCHEMBL14508615 0.71 KDR (0.51) RAB9ANPC1KDM4EADORA3ADORA1
SCHEMBL5957676 0.70 FGFR1 (0.65) RAB9ANPC1KDM4EMEN1KMT2A
SCHEMBL1901480 0.70 RAB9A (1.00) RAB9ANPC1KDM4EMEN1KMT2A
SCHEMBL29820118 0.70 RAB9A (1.00) RAB9ANPC1KDM4EMEN1KMT2A
SCHEMBL6741892 0.70 CYP19A1 (0.64) RAB9ANPC1KDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060004011-A1 Indolyl pyrazinone derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis BAYER PHARMACEUTICALS CORPORATION (US) 2006-01-05 US disclosed
EP-1565455-A1 INDOLYL PYRAZINONE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS Bayer Pharmaceuticals Corporation (US) 2005-08-24 EP disclosed
WO-2004043950-A1 INDOLYL PYRAZINONE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS BAYER PHARMACEUTICALS CORPORATION (US) 2004-05-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004011-A1 Indolyl pyrazinone derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis MKI67, VEGFA, FLT1 RAB9A 2009/4885NPC1 2143/4885KDM4E 4059/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.